Strong Revenue and Profit Growth Might Change the Case for Investing in SMIC (SEHK:981)

• Semiconductor Manufacturing International Corporation recently announced earnings for the nine months ended September 30, 2025, reporting sales of CNY 49.51 billion and net income of CNY 3.82 billion, both higher than the same period last year.
• This strong financial result reflects improved business performance and suggests the company may be benefiting from rising demand and operational efficiencies.
• We'll examine how this substantial revenue and profit growth could influence key elements of SMIC's existing investment narrative.

Outshine the giants: these 27 early-stage AI stocks could fund your retirement.

Semiconductor Manufacturing International Investment Narrative Recap

To be a shareholder of Semiconductor Manufacturing International Corporation (SMIC), you need to believe the company can capture China’s domestic chip growth and mitigate margin pressure through scale and supply chain localization. The latest earnings result, showing both sales and net income rising year-on-year, directly addresses the biggest short term catalyst, SMIC’s ability to leverage capacity expansion for higher utilization and revenue. However, this positive update does not remove the significant risk tied to SMIC’s reliance on Chinese market demand, which leaves earnings exposed during any sector downturn.

Of the recent announcements, SMIC’s third quarter earnings release stands out as most relevant. The reported revenue and profit gains, confirmed in the November update, support the view that SMIC’s aggressive wafer capacity expansion is translating into higher sales and possibly improved operational efficiencies. This result aligns with a fundamental narrative catalyst: sustained volume growth from domestic clients in key sectors like automotive and consumer electronics.

In contrast, investors should remain mindful of how quickly SMIC’s profitability could be challenged if domestic demand falters or sector volatility increases...

Read the full narrative on Semiconductor Manufacturing International (it's free!)

Semiconductor Manufacturing International's outlook anticipates $12.6 billion in revenue and $1.5 billion in earnings by 2028. This is based on a projected annual revenue growth rate of 12.7% and an earnings increase of $923.1 million from current earnings of $576.9 million.

Uncover how Semiconductor Manufacturing International's forecasts yield a HK$59.57 fair value, a 19% downside to its current price.

Exploring Other Perspectives

Seven fair value estimates from the Simply Wall St Community fall between HK$46.31 and HK$89.97 per share. Despite broad optimism about revenue and capacity expansion, the concentration of SMIC’s earnings in China remains a pivotal consideration for long term performance.

Explore 7 other fair value estimates on Semiconductor Manufacturing International - why the stock might be worth as much as 22% more than the current price!

Build Your Own Semiconductor Manufacturing International Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Semiconductor Manufacturing International research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Semiconductor Manufacturing International research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Semiconductor Manufacturing International's overall financial health at a glance.

Searching For A Fresh Perspective?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• We've found 15 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com